vs
Nurix Therapeutics, Inc.（NRIX）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
RECURSION PHARMACEUTICALS, INC.的季度营收约是Nurix Therapeutics, Inc.的2.6倍（$35.5M vs $13.6M），RECURSION PHARMACEUTICALS, INC.净利率更高（-304.2% vs -576.1%，领先271.9%），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs 2.2%），RECURSION PHARMACEUTICALS, INC.自由现金流更多（$-47.3M vs $-73.0M），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs -9.5%）
Nurix Therapeutics是一家临床阶段生物制药企业，专注于发现、开发及商业化针对癌症、免疫疾病等存在重大未满足医疗需求的新型靶向蛋白降解疗法，依托专有的E3泛素连接酶调节技术推进管线研发，与全球多家制药企业达成合作。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
NRIX vs RXRX — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $13.6M | $35.5M |
| 净利润 | $-78.2M | $-108.1M |
| 毛利率 | — | 59.8% |
| 营业利润率 | -612.0% | -304.8% |
| 净利率 | -576.1% | -304.2% |
| 营收同比 | 2.2% | 681.7% |
| 净利润同比 | -33.6% | 39.6% |
| 每股收益（稀释后） | $-0.83 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $13.6M | $35.5M | ||
| Q3 25 | $7.9M | $5.2M | ||
| Q2 25 | $44.1M | $19.2M | ||
| Q1 25 | $18.5M | $14.7M | ||
| Q4 24 | $13.3M | $4.5M | ||
| Q3 24 | $12.6M | $26.1M | ||
| Q2 24 | $12.1M | $14.4M | ||
| Q1 24 | $16.6M | $13.8M |
| Q4 25 | $-78.2M | $-108.1M | ||
| Q3 25 | $-86.4M | $-162.3M | ||
| Q2 25 | $-43.5M | $-171.9M | ||
| Q1 25 | $-56.4M | $-202.5M | ||
| Q4 24 | $-58.5M | $-178.9M | ||
| Q3 24 | $-49.0M | $-95.8M | ||
| Q2 24 | $-44.5M | $-97.5M | ||
| Q1 24 | $-41.5M | $-91.4M |
| Q4 25 | — | 59.8% | ||
| Q3 25 | — | -183.8% | ||
| Q2 25 | — | -4.9% | ||
| Q1 25 | — | -48.0% | ||
| Q4 24 | — | -181.4% | ||
| Q3 24 | — | 53.7% | ||
| Q2 24 | — | 36.2% | ||
| Q1 24 | — | 19.1% |
| Q4 25 | -612.0% | -304.8% | ||
| Q3 25 | -1157.7% | -3327.6% | ||
| Q2 25 | -109.7% | -916.8% | ||
| Q1 25 | -340.7% | -1297.9% | ||
| Q4 24 | -486.7% | -4042.4% | ||
| Q3 24 | -433.8% | -377.1% | ||
| Q2 24 | -401.4% | -697.4% | ||
| Q1 24 | -272.6% | -698.4% |
| Q4 25 | -576.1% | -304.2% | ||
| Q3 25 | -1094.8% | -3135.3% | ||
| Q2 25 | -98.7% | -894.2% | ||
| Q1 25 | -305.4% | -1373.3% | ||
| Q4 24 | -440.7% | -3935.5% | ||
| Q3 24 | -388.9% | -367.5% | ||
| Q2 24 | -368.4% | -676.6% | ||
| Q1 24 | -250.3% | -662.4% |
| Q4 25 | $-0.83 | $-0.17 | ||
| Q3 25 | $-1.03 | $-0.36 | ||
| Q2 25 | $-0.52 | $-0.41 | ||
| Q1 25 | $-0.67 | $-0.50 | ||
| Q4 24 | $-0.74 | $-0.56 | ||
| Q3 24 | $-0.67 | $-0.34 | ||
| Q2 24 | $-0.71 | $-0.40 | ||
| Q1 24 | $-0.76 | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $247.0M | $743.3M |
| 总债务越低越好 | — | $9.6M |
| 股东权益账面价值 | $538.7M | $1.1B |
| 总资产 | $688.1M | $1.5B |
| 负债/权益比越低杠杆越低 | — | 0.01× |
8季度趋势，按日历期对齐
| Q4 25 | $247.0M | $743.3M | ||
| Q3 25 | $78.4M | $659.8M | ||
| Q2 25 | $84.3M | $525.1M | ||
| Q1 25 | $75.9M | $500.5M | ||
| Q4 24 | $110.0M | $594.4M | ||
| Q3 24 | $99.0M | $427.6M | ||
| Q2 24 | $116.8M | $474.3M | ||
| Q1 24 | $49.8M | $296.3M |
| Q4 25 | — | $9.6M | ||
| Q3 25 | — | $11.9M | ||
| Q2 25 | — | $14.2M | ||
| Q1 25 | — | $16.4M | ||
| Q4 24 | — | $19.0M | ||
| Q3 24 | — | $20.5M | ||
| Q2 24 | — | $22.9M | ||
| Q1 24 | — | — |
| Q4 25 | $538.7M | $1.1B | ||
| Q3 25 | $372.3M | $1.0B | ||
| Q2 25 | $447.6M | $919.1M | ||
| Q1 25 | $480.9M | $933.9M | ||
| Q4 24 | $527.0M | $1.0B | ||
| Q3 24 | $376.9M | $524.6M | ||
| Q2 24 | $370.7M | $584.4M | ||
| Q1 24 | $168.7M | $401.2M |
| Q4 25 | $688.1M | $1.5B | ||
| Q3 25 | $522.5M | $1.4B | ||
| Q2 25 | $591.6M | $1.3B | ||
| Q1 25 | $615.0M | $1.3B | ||
| Q4 24 | $669.3M | $1.4B | ||
| Q3 24 | $513.6M | $726.5M | ||
| Q2 24 | $511.0M | $775.9M | ||
| Q1 24 | $312.7M | $557.8M |
| Q4 25 | — | 0.01× | ||
| Q3 25 | — | 0.01× | ||
| Q2 25 | — | 0.02× | ||
| Q1 25 | — | 0.02× | ||
| Q4 24 | — | 0.02× | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.04× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-67.8M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | $-73.0M | $-47.3M |
| 自由现金流率自由现金流/营收 | -537.4% | -133.1% |
| 资本支出强度资本支出/营收 | 37.8% | 3.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-263.5M | $-378.3M |
8季度趋势，按日历期对齐
| Q4 25 | $-67.8M | $-46.1M | ||
| Q3 25 | $-57.4M | $-117.4M | ||
| Q2 25 | $-63.2M | $-76.4M | ||
| Q1 25 | $-61.1M | $-132.0M | ||
| Q4 24 | $-48.8M | $-115.4M | ||
| Q3 24 | $-42.2M | $-59.2M | ||
| Q2 24 | $-39.7M | $-82.2M | ||
| Q1 24 | $-42.0M | $-102.3M |
| Q4 25 | $-73.0M | $-47.3M | ||
| Q3 25 | $-60.1M | $-117.6M | ||
| Q2 25 | $-65.8M | $-79.6M | ||
| Q1 25 | $-64.6M | $-133.8M | ||
| Q4 24 | $-50.9M | $-116.7M | ||
| Q3 24 | $-44.5M | $-63.8M | ||
| Q2 24 | $-41.6M | $-83.4M | ||
| Q1 24 | $-44.8M | $-109.0M |
| Q4 25 | -537.4% | -133.1% | ||
| Q3 25 | -761.3% | -2272.5% | ||
| Q2 25 | -149.4% | -413.9% | ||
| Q1 25 | -349.9% | -907.4% | ||
| Q4 24 | -382.8% | -2567.7% | ||
| Q3 24 | -353.7% | -244.6% | ||
| Q2 24 | -344.4% | -578.5% | ||
| Q1 24 | -270.3% | -789.9% |
| Q4 25 | 37.8% | 3.5% | ||
| Q3 25 | 34.3% | 4.7% | ||
| Q2 25 | 6.1% | 16.4% | ||
| Q1 25 | 18.9% | 12.4% | ||
| Q4 24 | 15.8% | 28.6% | ||
| Q3 24 | 18.6% | 17.5% | ||
| Q2 24 | 16.0% | 8.2% | ||
| Q1 24 | 17.4% | 48.2% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NRIX
| Pfizer | $11.9M | 88% |
| Gilead Agreement | $1.7M | 13% |
RXRX
暂无分部数据
